159 related articles for article (PubMed ID: 9443665)
1. Anti-HIV activity of adefovir (PMEA) and PMPA in combination with antiretroviral compounds: in vitro analyses.
Mulato AS; Cherrington JM
Antiviral Res; 1997 Nov; 36(2):91-7. PubMed ID: 9443665
[TBL] [Abstract][Full Text] [Related]
2. Chemokines, nitric oxide and antiarthritic effects of 9-(2-phosphonomethoxyethyl)adenine (Adefovir).
Zídek Z; Franková D; Holý A
Eur J Pharmacol; 1999 Jul; 376(1-2):91-100. PubMed ID: 10440094
[TBL] [Abstract][Full Text] [Related]
3. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA.
Wainberg MA; Miller MD; Quan Y; Salomon H; Mulato AS; Lamy PD; Margot NA; Anton KE; Cherrington JM
Antivir Ther; 1999; 4(2):87-94. PubMed ID: 10682153
[TBL] [Abstract][Full Text] [Related]
4. Antiviral activities of 9-R-2-phosphonomethoxypropyl adenine (PMPA) and bis(isopropyloxymethylcarbonyl)PMPA against various drug-resistant human immunodeficiency virus strains.
Srinivas RV; Fridland A
Antimicrob Agents Chemother; 1998 Jun; 42(6):1484-7. PubMed ID: 9624498
[TBL] [Abstract][Full Text] [Related]
5. Tenofovir, adefovir, and zidovudine susceptibilities of primary human immunodeficiency virus type 1 isolates with non-B subtypes or nucleoside resistance.
Palmer S; Margot N; Gilbert H; Shaw N; Buckheit R; Miller M
AIDS Res Hum Retroviruses; 2001 Aug; 17(12):1167-73. PubMed ID: 11522186
[TBL] [Abstract][Full Text] [Related]
6. Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA.
Robbins BL; Srinivas RV; Kim C; Bischofberger N; Fridland A
Antimicrob Agents Chemother; 1998 Mar; 42(3):612-7. PubMed ID: 9517941
[TBL] [Abstract][Full Text] [Related]
7. Potent differentiation-inducing properties of the antiretroviral agent 9-(2-phosphonylmethoxyethyl) adenine (PMEA) in the rat choriocarcinoma (RCHO) tumor cell model.
Hatse S; Naesens L; De Clercq E; Balzarini J
Biochem Pharmacol; 1998 Oct; 56(7):851-9. PubMed ID: 9774147
[TBL] [Abstract][Full Text] [Related]
8. Prevention of murine AIDS development by (R)-9-(2-phosphonylmethoxypropyl)adenine.
Suruga Y; Makino M; Okada Y; Tanaka H; De Clercq E; Baba M
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Aug; 18(4):316-22. PubMed ID: 9704936
[TBL] [Abstract][Full Text] [Related]
9. Pronounced in vitro and in vivo antiretroviral activity of 5-substituted 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy] pyrimidines.
Balzarini J; Schols D; Van Laethem K; De Clercq E; Hocková D; Masojidkova M; Holý A
J Antimicrob Chemother; 2007 Jan; 59(1):80-6. PubMed ID: 17124193
[TBL] [Abstract][Full Text] [Related]
10. In vitro selection and molecular characterization of human immunodeficiency virus type 1 with reduced sensitivity to 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA).
Foli A; Sogocio KM; Anderson B; Kavlick M; Saville MW; Wainberg MA; Gu Z; Cherrington JM; Mitsuya H; Yarchoan R
Antiviral Res; 1996 Oct; 32(2):91-8. PubMed ID: 8891168
[TBL] [Abstract][Full Text] [Related]
11. Hydroxyurea enhances the activities of didanosine, 9-[2-(phosphonylmethoxy)ethyl]adenine, and 9-[2-(phosphonylmethoxy)propyl]adenine against drug-susceptible and drug-resistant human immunodeficiency virus isolates.
Palmer S; Shafer RW; Merigan TC
Antimicrob Agents Chemother; 1999 Aug; 43(8):2046-50. PubMed ID: 10428934
[TBL] [Abstract][Full Text] [Related]
12. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
Taylor DL; Ahmed PS; Tyms AS; Wood LJ; Kelly LA; Chambers P; Clarke J; Bedard J; Bowlin TL; Rando RF
Antivir Chem Chemother; 2000 Jul; 11(4):291-301. PubMed ID: 10950391
[TBL] [Abstract][Full Text] [Related]
13. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from AIDS patients after prolonged adefovir dipivoxil therapy.
Mulato AS; Lamy PD; Miller MD; Li WX; Anton KE; Hellmann NS; Cherrington JM
Antimicrob Agents Chemother; 1998 Jul; 42(7):1620-8. PubMed ID: 9660994
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of nucleoside phosphonates and their analogs and prodrugs for inhibition of orthopoxvirus replication.
Keith KA; Hitchcock MJ; Lee WA; Holý A; Kern ER
Antimicrob Agents Chemother; 2003 Jul; 47(7):2193-8. PubMed ID: 12821467
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of murine AIDS by a heterodinucleotide of azidothymidine and 9-(R)-2-(phosphonomethoxypropyl)adenine.
Rossi L; Serafini S; Franchetti P; Casabianca A; Orlandi C; Schiavano GF; Carnevali A; Magnani M
J Antimicrob Chemother; 2002 Nov; 50(5):639-47. PubMed ID: 12407119
[TBL] [Abstract][Full Text] [Related]
16. Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections.
De Clercq E
Clin Microbiol Rev; 2003 Oct; 16(4):569-96. PubMed ID: 14557287
[TBL] [Abstract][Full Text] [Related]
17. Effect of PMPA and PMEA on the kinetics of viral load in simian immunodeficiency virus-infected macaques.
Silvera P; Racz P; Racz K; Bischofberger N; Crabbs C; Yalley-Ogunro J; Greenhouse J; Jiang JB; Lewis MG
AIDS Res Hum Retroviruses; 2000 May; 16(8):791-800. PubMed ID: 10826485
[TBL] [Abstract][Full Text] [Related]
18. Potent antitumor activity of the acyclic nucleoside phosphonate 9-(2-phosphonylmethoxyethyl)adenine in choriocarcinoma-bearing rats.
Hatse S; Naesens L; Degrève B; Segers C; Vandeputte M; Waer M; De Clercq E; Balzarini J
Int J Cancer; 1998 May; 76(4):595-600. PubMed ID: 9590139
[TBL] [Abstract][Full Text] [Related]
19. Antiviral potential of a new generation of acyclic nucleoside phosphonates, the 6-[2-(phosphonomethoxy)alkoxy]-2,4-diaminopyrimidines.
De Clercq E; Andrei G; Balzarini J; Leyssen P; Naesens L; Neyts J; Pannecouque C; Snoeck R; Ying C; Hocková D; Holý A
Nucleosides Nucleotides Nucleic Acids; 2005; 24(5-7):331-41. PubMed ID: 16247948
[TBL] [Abstract][Full Text] [Related]
20. Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV- infected subjects: ACTG 884.
Fletcher CV; Acosta EP; Cheng H; Haubrich R; Fischl M; Raasch R; Mills C; Hu XJ; Katzenstein D; Remmel RP; Gulick RM;
AIDS; 2000 Nov; 14(16):2495-501. PubMed ID: 11101060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
